These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29453932)

  • 1. Neurotrophin-3 restores synaptic plasticity in the striatum of a mouse model of Huntington's disease.
    Gómez-Pineda VG; Torres-Cruz FM; Vivar-Cortés CI; Hernández-Echeagaray E
    CNS Neurosci Ther; 2018 Apr; 24(4):353-363. PubMed ID: 29453932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotrophin-3 Rescues Striatal Synaptic Plasticity in Model of Neurodegeneration by PLC Signaling Activation.
    Gómez-Pineda VG; Nieto-Mendoza E; Torres-Cruz FM; Hernández-Echeagaray E
    CNS Neurol Disord Drug Targets; 2024; 23(12):1488-1498. PubMed ID: 38859788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo mitochondrial inhibition alters corticostriatal synaptic function and the modulatory effects of neurotrophins.
    Mendoza E; Miranda-Barrientos JA; Vázquez-Roque RA; Morales-Herrera E; Ruelas A; De la Rosa G; Flores G; Hernández-Echeagaray E
    Neuroscience; 2014 Nov; 280():156-70. PubMed ID: 25241069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do BDNF and NT-4/5 exert synergistic or occlusive effects on corticostriatal transmission in a male mouse model of Huntington's disease?
    Torres-Cruz FM; Mendoza E; Vivar-Cortés IC; García-Sierra F; Hernández-Echeagaray E
    J Neurosci Res; 2019 Dec; 97(12):1665-1677. PubMed ID: 31392756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease.
    Dalbem A; Silveira CV; Pedroso MF; Breda RV; Werne Baes CV; Bartmann AP; da Costa JC
    Brain Res; 2005 Jun; 1047(2):148-58. PubMed ID: 15901483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease.
    Pérez-Navarro E; Canudas AM; Akerund P; Alberch J; Arenas E
    J Neurochem; 2000 Nov; 75(5):2190-9. PubMed ID: 11183872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotrophin-3 modulates synaptic transmission.
    Hernández-Echeagaray E
    Vitam Horm; 2020; 114():71-89. PubMed ID: 32723551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
    Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
    J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine.
    Calabresi P; Gubellini P; Picconi B; Centonze D; Pisani A; Bonsi P; Greengard P; Hipskind RA; Borrelli E; Bernardi G
    J Neurosci; 2001 Jul; 21(14):5110-20. PubMed ID: 11438586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuronal adenosine A
    Domenici MR; Chiodi V; Averna M; Armida M; Pèzzola A; Pepponi R; Ferrante A; Bader M; Fuxe K; Popoli P
    Purinergic Signal; 2018 Sep; 14(3):235-243. PubMed ID: 29770921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia.
    Akopian G; Crawford C; Beal MF; Cappelletti M; Jakowec MW; Petzinger GM; Zheng L; Gheorghe SL; Reichel CM; Chow R; Walsh JP
    J Neurosci; 2008 Sep; 28(38):9585-97. PubMed ID: 18799690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NT-4/5 antagonizes the BDNF modulation of corticostriatal transmission: Role of the TrkB.T1 receptor.
    Torres-Cruz FM; César Vivar-Cortés I; Moran I; Mendoza E; Gómez-Pineda V; García-Sierra F; Hernández-Echeagaray E
    CNS Neurosci Ther; 2019 May; 25(5):621-631. PubMed ID: 30666798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons.
    Picconi B; Passino E; Sgobio C; Bonsi P; Barone I; Ghiglieri V; Pisani A; Bernardi G; Ammassari-Teule M; Calabresi P
    Neurobiol Dis; 2006 Apr; 22(1):143-52. PubMed ID: 16326108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of neurotrophin-3 triggers sprouting, decreases the levels of TrkA and TrkC, and inhibits epileptogenesis and activity-dependent axonal growth in adult rats.
    Xu B; Michalski B; Racine RJ; Fahnestock M
    Neuroscience; 2002; 115(4):1295-308. PubMed ID: 12453498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.
    Blum D; Gall D; Galas MC; d'Alcantara P; Bantubungi K; Schiffmann SN
    J Neurosci; 2002 Oct; 22(20):9122-33. PubMed ID: 12388620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of striatal dopaminergic function. III: Pre- and postnatal development of striatal and cortical mRNAs for the neurotrophin receptors trkBTK+ and trkC and their regulation by synaptic dopamine.
    Jung AB; Bennett JP
    Brain Res Dev Brain Res; 1996 Jul; 94(2):133-43. PubMed ID: 8836571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module.
    Garcia M; Vanhoutte P; Pages C; Besson MJ; Brouillet E; Caboche J
    J Neurosci; 2002 Mar; 22(6):2174-84. PubMed ID: 11896157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotrophin-3 Enhances the Synaptic Organizing Function of TrkC-Protein Tyrosine Phosphatase σ in Rat Hippocampal Neurons.
    Ammendrup-Johnsen I; Naito Y; Craig AM; Takahashi H
    J Neurosci; 2015 Sep; 35(36):12425-31. PubMed ID: 26354911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ginsenoside Rg1 exerts neuroprotective effects in 3-nitropronpionic acid-induced mouse model of Huntington's disease via suppressing MAPKs and NF-κB pathways in the striatum.
    Yang X; Chu SF; Wang ZZ; Li FF; Yuan YH; Chen NH
    Acta Pharmacol Sin; 2021 Sep; 42(9):1409-1421. PubMed ID: 33214696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection by ADAM10 inhibition requires TrkB signaling in the Huntington's disease hippocampus.
    Scolz A; Vezzoli E; Villa M; Talpo F; Cazzola J; Raffin F; Cordiglieri C; Falqui A; Pepe G; Maglione V; Besusso D; Biella G; Zuccato C
    Cell Mol Life Sci; 2024 Aug; 81(1):333. PubMed ID: 39112663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.